| 臺大學術典藏 |
2022-02-21T03:52:38Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Liao B.-C.; JIH-HSIANG LEE; Lin C.-C.; Chen Y.-F.; Chang C.-H.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; JIH-HSIANG LEE; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:34Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non�VSmall-cell Lung Cancer Patients
|
Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Liao W.-Y.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:34Z |
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
|
Liao B.-C.; Bai Y.-Y.; JIH-HSIANG LEE; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Chih-Hsin Yang J.; Yang P.-C. |
| 臺大學術典藏 |
2022-02-21T03:52:33Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
JIH-HSIANG LEE; Chen H.-Y.; Hsu F.-M.; Chen J.-S.; Liao W.-Y.; Shih J.-Y.; Yu C.-J.; Chen K.-Y.; Tsai T.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:33Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; JIH-HSIANG LEE; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:30Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-14T07:10:41Z |
Successful management of a ROS1-rearranged pulmonary pleomorphic carcinoma using serial tyrosine kinase inhibitors
|
Wu C.-W.; Yang C.-Y.; YIH-LEONG CHANG; Shih J.-Y. |
| 臺大學術典藏 |
2022-02-14T07:10:40Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-14T07:10:39Z |
Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1
|
Chung K.-P.; Huang Y.-L.; Chen Y.-J.; Juan Y.-H.; Hsu C.-L.; Nakahira K.; Huang Y.-T.; Lin M.-W.; Wu S.-G.; Shih J.-Y.; YIH-LEONG CHANG; Yu C.-J. |
| 臺大學術典藏 |
2022-02-14T07:10:38Z |
Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer
|
Lin C.-Y.; Huang K.-Y.; Lin Y.-C.; Yang S.-C.; Chung W.-C.; YIH-LEONG CHANG; Shih J.-Y.; Ho C.-C.; Lin C.-A.; Shih C.-C.; Chang Y.-H.; Kao S.-H.; Yang P.-C. |
| 臺大學術典藏 |
2022-01-22T00:04:55Z |
Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer
|
Chang, L. K.; Kuo, Y. W.; Wu, S. G.; Chung, K. P.; Shih, J. Y. |
| 臺大學術典藏 |
2022-01-14T03:59:36Z |
Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers
|
JO-PAI CHEN; Lo Y.; Yu C.-J.; Hsu C.; Shih J.-Y.; Yang C.-H. |
| 臺大學術典藏 |
2022-01-08T04:31:30Z |
Clinicopathological features and survival outcomes of primary pulmonary invasive mucinous adenocarcinoma
|
Gow C.-H.; MIN-SHU HSIEH; Liu Y.-N.; Lee Y.-H.; Shih J.-Y. |
| 國立成功大學 |
2022 |
miR-21 upregulation exacerbates pressure overload-induced cardiac hypertrophy in aged hearts
|
Chang, W.-T.;Shih, J.-Y.;Lin, Y.-W.;Huang, T.-L.;Chen, Z.-C.;Chen, Chen C.-L.;Chu, J.-S.;Liu, P.Y. |
| 國立成功大學 |
2022 |
An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline
|
Chang, W.-T.;Liu, C.-F.;Feng, Y.-H.;Liao, C.-T.;Wang, J.-J.;Chen, Z.-C.;Lee, H.-C.;Shih, J.-Y. |
| 國立成功大學 |
2022 |
Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients with Prostate Cancer
|
Kan, W.-C.;Hsieh, K.-L.;Chen, Y.-C.;Ho, C.H.;Hong, C.-S.;Chiang, Chiang C.-Y.;Wu, N.-C.;Chen, M.;Shih, J.-Y.;Chen, Z.-C.;Chang, W.-T. |
| 國立成功大學 |
2022 |
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities
|
Wu, N.-C.;Feng, Y.-H.;Kuo, Y.H.;Chen, W.-Y.;Wu, H.-C.;Huang, C.-T.;Wang, Wang W.-C.;Kang, N.-W.;Shih, J.-Y.;Chen, Z.-C.;Chang, W.-T. |
| 國立成功大學 |
2022 |
Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3
|
Chang, W.-T.;Shih, J.-Y.;Lin, Y.-W.;Chen, Z.-C.;Kan, W.-C.;Lin, T.-H.;Hong, C.-S. |
| 國立成功大學 |
2022 |
Regular use of aspirin is associated with a lower cardiovascular risk in prostate cancer patients receiving gonadotropin-releasing hormone therapy
|
Chang, W.-T.;Hong, C.-S.;Hsieh, K.-L.;Chen, Y.-C.;Ho, C.;Shih, J.-Y.;Kan, W.-C.;Chen, Z.-C.;Lin, Y.-C. |
| 國立成功大學 |
2022 |
Deletion of MicroRNA-21 Impairs Neovascularization Following Limb Ischemia: From Bedside to Bench
|
Chang, W.-T.;Lin, Y.-W.;Huang, P.-S.;Lin, Y.-C.;Tseng, S.-Y.;Chao, T.-H.;Chen, Z.-C.;Shih, J.-Y.;Hong, C.-S. |
| 國立成功大學 |
2022 |
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
|
Su, P.-L.;Chang, G.-C.;Hsiao, S.-H.;Hsia, T.-C.;Lin, M.-C.;Lin, M.-H.;Shih, J.-Y.;Yang, C.-T.;Yang, S.-H.;Chen, Y.-M. |
